



Citi Pharma Limited

April 30, 2025

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi.

Subject: FINANCIAL RESULTS FOR THE NINE MONTHS PERIOD ENDED MARCH 31, 2025

Dear Sir,

We have to inform you that the Board of Directors of the company in their meeting held on April 30, 2025 at Lahore have approved the financial statements for the period ended on March 31, 2025 and recommended the following.

Cash Dividend	Nil
Bonus Shares	Nil
Right Shares	Nil
Any other entitlement/corporate action	Nil
Any other Price sensitive information	Nil

Financial Performance:

While reviewing the Company financial performance for the period ended, the Board appreciated the efforts of the management in the area of operation and posting the financial results.

Financial results of the company for the period ended March 31, 2025 are enclosed.

Nine Months report of the Company for the period ended March 31, 2025 will be transmitted through PUCARS separately, within the specified time.

Yours Sincerely,

Ghulam Dustgeer
Company Secretary



Cc:

Executive Director/HOD, Offsite-II, Department
Supervision Division, Securities & Exchange Commission of Pakistan

CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)
FOR THE NINE MONTHS ENDED MARCH 31, 2025

Notes	Three month ended		Nine Months Ended	
	March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024
	Rupees			
Sales- Net	3,341,107,922	3,558,873,609	10,100,185,059	9,535,266,706
Cost of Sales	(2,852,435,507)	(3,087,343,974)	(8,643,865,934)	(8,192,103,683)
Gross Profit	488,672,415	471,529,635	1,456,319,125	1,343,163,023
Administrative Expenses	57,257,879	55,242,892	161,904,092	154,757,727
Selling Expenses	35,876,526	30,758,748	119,703,970	100,497,146
	(93,134,405)	(85,601,640)	(281,608,062)	(255,254,873)
Operating Profit	395,538,010	385,927,995	1,174,711,063	1,087,908,150
Financial [Cost] /Income	(99,063,295)	(43,826,747)	(231,505,104)	(200,800,962)
	296,474,715	342,101,248	943,205,959	887,107,188
Other Income/(Loss)	23,173,268	49,340,992	165,818,206	312,952,864
	319,647,983	391,442,239	1,109,024,165	1,200,060,051
Other Expenses	(25,431,095)	(26,569,358)	(80,335,099)	(82,062,737)
Profit before income taxes and final tax	294,216,887	364,872,881	1,028,689,066	1,117,997,315
Taxation - Final taxes	-	-	(4,004)	(255,970)
Profit before income tax	294,216,887	364,872,881	1,028,685,062	1,117,741,345
Taxation - Income tax	(73,841,712)	(153,527,794)	(349,842,286)	(436,344,074)
Profit after income tax	220,375,175	211,345,087	678,842,776	681,397,271
Earnings per share (EPS)				
- Basic and Diluted	0.96	0.93	2.97	2.98



CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)
FOR THE NINE MONTHS ENDED MARCH 31, 2025

	Three month ended		Nine Months Ended	
	March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024
	Rupees			
Sales- Net	3,341,107,922	3,558,873,609	10,100,185,059	9,535,266,706
Cost of Sales	(2,852,435,507)	(3,087,343,974)	(8,643,865,934)	(8,192,103,683)
Gross Profit	488,672,415	471,529,635	1,456,319,125	1,343,163,023
Administrative Expenses	57,257,879	55,242,892	161,904,092	154,757,727
Selling Expenses	35,876,526	30,358,748	119,703,970	100,497,146
	(93,134,405)	(85,601,640)	(281,608,062)	(255,254,873)
Operating Profit	395,538,010	385,927,995	1,174,711,063	1,087,908,150
Financial (Cost) /Income	(99,063,295)	(43,826,747)	(231,505,104)	(200,800,962)
	296,474,715	342,101,248	943,205,959	887,107,188
Other Income/(Loss)	23,173,268	49,340,992	165,818,206	312,952,864
	319,647,983	391,442,239	1,109,024,165	1,200,060,051
Other Expenses	(25,431,096)	(26,569,358)	(80,335,099)	(82,062,737)
Profit before income taxes and	294,216,887	364,872,881	1,028,689,066	1,117,997,315
Taxation - Final taxes	-	-	(4,004)	(255,970)
Profit before income tax	294,216,887	364,872,881	1,028,685,062	1,117,741,345
Taxation - Income tax	(73,841,712)	(153,527,794)	(349,842,286)	(436,344,074)
Profit after income tax	220,375,175	211,345,087	678,842,776	681,397,271
Earnings per share (EPS)				
- Basic and Diluted	0.96	0.93	2.97	2.98



CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION
AS AT MARCH 31, 2025

	March 31, 2025 (Un-audited)	June 30, 2024 (Audited)
	Rupees	
EQUITY AND LIABILITIES		
SHARE CAPITAL AND RESERVES		
Authorized Capital:		
300,000,000 Ordinary shares of Rs. 10/- each	3,000,000,000	3,000,000,000
Share Capital and Reserves:		
228,461,200 (June 2024: 228,461,200) Ordinary Shares Of Rs. 10/- Each	2,284,612,000	2,284,612,000
Share Premium	1,391,532,000	1,391,532,000
Revenue Reserves-Unappropriated Profits	1,584,034,793	1,647,690,917
Revaluation Surplus On Land	309,294,525	309,294,525
	5,569,473,318	5,633,129,442
NON-CURRENT LIABILITIES		
Long Term Financing - Secured	-	-
Deferred Liabilities	231,875,049	206,710,153
Deferred Grant	-	-
Lease Liabilities	22,490,146	-
	254,365,195	206,710,153
CURRENT LIABILITIES		
Trade and Other Payables	4,459,171,395	3,563,513,261
Due to Related Parties	3,272,000	43,420,000
Short Term Borrowings-Secured	2,909,827,624	1,393,095,588
Current Portion of Long Term Liabilities-Secured	7,159,574	18,865,031
Dividend Payable	2,502,154	1,389,901
Accrued Mark Up	40,375,023	71,473,816
Provision For Taxation	355,951,551	470,831,450
	7,778,259,321	5,563,589,047
Contingencies and Commitments	-	-
TOTAL EQUITY AND LIABILITIES	13,602,097,834	11,402,428,642
ASSETS		
NON CURRENT ASSETS		
Property, Plant and Equipment	3,358,895,928	3,399,650,337
Capital Work in Progress	280,162,640	152,599,615
Long Term Security Deposits	28,985,917	20,217,776
Long Term Advance	254,540,900	254,540,900
	1,922,545,385	3,827,008,628
CURRENT ASSETS		
Stock in Trade	4,099,096,256	3,203,374,300
Trade Debts- Unsecured	3,501,606,184	2,160,059,406
Advances Deposits, Prepayments and Other Receivables	759,508,605	817,795,801
Short Term Investments	1,288,619,743	1,306,290,577
Cash And Bank Balances	30,721,661	87,899,930
	9,679,552,449	7,575,420,014
TOTAL ASSETS	13,602,097,834	11,402,428,642



CITI PHARMA LIMITED
 CONDENSED INTERIM STATEMENT OF COMPREHENSIVE INCOME (UN-AUDITED)
 FOR THE NINE MONTHS ENDED MARCH 31, 2025

	Three month ended		Nine Months Ended	
	March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024
	-----Rupees-----			
Profit for the period	220,375,175	211,345,087	678,842,776	681,397,271
Other comprehensive income for the period	-	-	-	-
Item that will not be reclassified subsequently to Profit or Loss				
Revaluation Surplus on Land	-	-	-	-
Total comprehensive income for the Period	220,375,175	211,345,087	678,842,776	681,397,271



CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF CASH FLOWS (UN-AUDITED)
FOR THE NINE MONTHS ENDED MARCH 31, 2025

March 31, 2025 March 31, 2024

Rupees

CASH FLOW FROM OPERATING ACTIVITIES

Profit Before Taxation for the period	1,028,689,066	1,117,997,315
Adjustments For Non-Cash Items And Other Line Items:		
Depreciation	119,267,634	92,441,621
Financial Charges	231,505,104	200,800,962
Accrued Interest Income	(7,510,295)	(7,956,623)
Unrealized Gain/Loss on Investment in Shares	4,536,958	(44,791,780)
Amortization and Extinguishment of Deferred Grant	(582,494)	(1,521,831)
Gratuity Expense	-	10,850,323
Worker's Profit Participation Fund	55,214,360	60,003,003
Worker's Welfare Fund	20,573,781	22,354,060
	423,015,049	332,179,735
Profit/ (Loss) before working capital changes	1,451,704,115	1,450,177,050
Effect of working capital changes		
Advances, Deposits And Prepayments	52,129,049	(44,172,154)
Trade Debits	(1,341,546,778)	25,549,584
Stock In Trade	(895,721,955)	(43,973,582)
Trade And Other Payables	888,640,295	866,100,509
	(1,296,499,389)	803,504,358
Financial Charges Paid	(262,603,897)	(219,790,127)
Income Tax Paid	(426,353,670)	(330,830,010)
Gratuity Paid	-	(244,050)
Worker's Profit Participation Fund	(68,780,302)	(54,091,160)
	(757,737,869)	(604,955,347)
Net cash flow from operating activities	(602,531,144)	1,648,726,060

CASH FLOW FROM INVESTING ACTIVITIES

Purchase Of Property, Plant & Equipment	(45,519,385)	(86,928,550)
Paid for Capital Work in Progress	(127,563,025)	(472,731,348)
Paid for Long Term Security Deposits	(8,768,141)	3,060,900
Short Term Investments	19,815,262	52,829,364
Net cash flow from investing activities	(162,035,289)	(503,769,634)

CASH FLOW FROM FINANCING ACTIVITIES

Long-term loans repaid	(12,859,000)	(44,108,110)
Due to Related Parties	(40,148,000)	(189,730,000)
Lease Rentals Paid	(8,727,657)	(2,857,977)
Dividend Paid	(741,386,647)	(569,763,099)
Short Term Borrowings	1,516,732,035	(285,669,691)
Net Cash flow From Investing Activities	713,610,732	(1,092,128,876)

Net Increase/ (decrease) in cash and cash equivalents

(50,957,701) 52,827,550

Cash and cash equivalents at beginning of the period

1,278,333,631 1,411,532,062

Cash and cash equivalents at end of the period

1,227,375,930 1,464,359,612

Cash and cash equivalents comprise of:

Cash in hand	2,601,846	454,055
Cash at banks	28,119,815	278,054,884
Short Term Investments	1,196,654,269	1,185,850,673
	1,227,375,930	1,464,359,612



CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY (UN-AUDITED)
FOR THE NINE MONTHS ENDED MARCH 31, 2025

PARTICULARS	SHARE CAPITAL	SHARE DEPOSIT MONEY	CAPITAL RESERVES		REVENUE RESERVES	TOTAL
			REVALUATION SURPLUS	SHARE PREMIUM	UN-APPROPRIATED PROFIT	

----- Rupees -----

Balance as at July 01, 2023	2,284,612,000	-	309,294,525	1,391,532,000	1,387,634,785	5,373,073,310
-----------------------------	---------------	---	-------------	---------------	---------------	---------------

Total Comprehensive Income for the nine months

Final Dividend Paid for the year ended June 2023 @ 15%

Profit for the period

Other comprehensive income

					(571,153,000)	(571,153,000)
-	-	-	-	-	681,397,271	681,397,271
-	-	-	-	-	-	-

Balance as at March 31, 2024

Total Comprehensive Income for the nine months

2,284,612,000	-	309,294,525	1,391,532,000	1,487,673,854	5,483,317,581
---------------	---	-------------	---------------	---------------	---------------

Balance as at July 01, 2024

Final Dividend Paid for the year ended June 2024 @ 32.5%

Profit for the period

Other comprehensive income

Balance as at March 31, 2025

2,284,612,000	-	309,294,525	1,391,532,000	1,647,690,317	5,633,129,442
-	-	-	-	(742,488,900)	(742,488,900)
-	-	-	-	678,842,776	678,842,776
-	-	-	-	-	-
2,284,612,000	-	309,294,525	1,391,532,000	1,584,034,793	5,569,473,318

